Alcon (SIX/NYSE: ALC), a global leader in eye care, has announced the full U.S. commercial availability of Voyager™ DSLT, the first and only Direct Selective Laser Trabeculoplasty (DSLT) device. This groundbreaking technology is poised to accelerate the use of laser therapy as a first-line treatment for glaucoma, making it accessible to a broader range of patients.
The Voyager DSLT device is fully automated, delivering 120 laser pulses efficiently without requiring the use of a gonio lens, a step typically necessary in manual SLT procedures. Designed to provide an exceptional experience for both patients and physicians, Voyager DSLT promises to streamline the treatment process. Attendees at the 2025 American Glaucoma Society (AGS) meeting in Washington, D.C., from February 26 to March 2, will have the opportunity to experience the device at Alcon’s booth (#29-32) and attend a launch event.
Dr. Inder Paul Singh, President of The Eye Centers of Racine and Kenosha, shared his positive experience with Voyager DSLT, stating, “I’ve been using Voyager DSLT since October 2024, and it has significantly impacted the way we use SLT in our practice. My patients appreciate the efficiency and comfort, and the device has been embraced by our staff, allowing us to treat more patients with this effective glaucoma therapy.”
Glaucoma is a leading cause of irreversible blindness worldwide, and the number of affected individuals in the U.S. is expected to rise from 5 million to 6.3 million by 2050. Early intervention is critical in managing the disease, with treatment options ranging from medication to surgery. Selective Laser Trabeculoplasty (SLT) is recognized by major medical societies, including the American Academy of Ophthalmology, as an effective first-line therapy. However, manual SLT has faced challenges, including lengthy treatment times and the need for specialized training, which have limited its widespread adoption.
Alcon’s Voyager DSLT aims to overcome these hurdles by offering an intuitive, automated system that simplifies the procedure and reduces the need for specialized training. The device incorporates SureTrac™ eye-tracking technology, ensuring precise and safe delivery of laser pulses to the eye’s trabecular meshwork, stimulating the eye’s natural healing response to improve fluid outflow and control intraocular pressure (IOP).
In clinical trials, Voyager DSLT demonstrated strong efficacy, with nearly 62% of patients remaining medication-free at 12 months and a high satisfaction rate among those who underwent treatment. A survey of 24 physicians who participated in a DSLT demo found that 96% would choose the treatment for themselves if they had glaucoma.
The Voyager DSLT device is now available for demonstration and purchase at the AGS 2025 meeting, and a special launch symposium, “Unlock First-line Glaucoma Care: Voyager™ DSLT,” will take place on February 27 at 7:15 a.m. EST in the Diamond Theatre.
Alcon is committed to advancing glaucoma treatment options, and Voyager DSLT adds to the company’s extensive glaucoma portfolio, which includes the Hydrus® Microstent and EX-PRESS® Glaucoma Filtration Device.
About Alcon
Alcon is a global leader in eye care, offering a wide range of products designed to enhance sight and improve lives. The company’s innovative portfolio includes surgical and vision care solutions, and it serves millions of people worldwide each year.
About Voyager™ DSLT
Voyager DSLT is an ophthalmic laser device designed for performing selective laser trabeculoplasty. It uses a Q-switched, 532 nm Nd:YAG laser to target the eye’s trabecular meshwork, improving aqueous outflow and lowering intraocular pressure.
Related topic:
Study Reveals Eye Changes as Key Indicator of Long COVID Effects
Genetics Influence Retinal Aging and Eye Disease
New Prescription Eye Drop Vuity Offers Hope for Presbyopia Sufferers
